Specifically, SFRP1 downregulation may relieve its inhibitory effect on tumor cell proliferation while diminishing the inherent anti-tumor metabolic capacity of BA tissue, thus promoting PAAD progression. The gene discussed is SFRP1; the disease is pancreatic adenocarcinoma.